Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Hypoport SE

Start price
Target price
Perf. (%)
€78.45
23.09.22
-
23.10.22
13.58%
24.10.22

Risky Investment
buy
Intra-Cellular Therapies Inc.

Start price
Target price
Perf. (%)
€44.49
23.09.22
€80.00
31.07.25
28.12%
05.05.23

Could be very worthwhile Investment >20% year
Hypoport SE

Start price
Target price
Perf. (%)
€91.15
23.09.22
€70.00
23.09.23
55.68%
30.05.23

buy
Pierre & Vacances S.A.

Start price
Target price
Perf. (%)
€0.80
23.09.22
€1.20
23.09.23
60.50%
24.09.23

Could be worthwhile Investment >10% per year
buy
SPI Energy Co Ltd ADR

Start price
Target price
Perf. (%)
€1.87
22.09.22
-
22.09.23
-29.50%
01.10.22

Risky Investment
buy
Mag Silver Corp.

Start price
Target price
Perf. (%)
€13.06
21.09.22
-
21.10.26
-36.42%
11.03.24

Could be worthwhile Investment >10% per year
buy
Intercept Pharmaceuticals

Start price
Target price
Perf. (%)
€15.08
21.09.22
-
21.09.23
-4.44%
01.10.22

Risky Investment
flatexDEGIRO AG

Start price
Target price
Perf. (%)
€9.18
20.09.22
€6.00
20.09.23
0.33%
01.10.22

Could be worthwhile Investment >10% per year
Good culture
Below average Management
Little innovation
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.05
20.09.22
€1.80
20.09.23
36.59%
19.11.22

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Inovio Pharma

Start price
Target price
Perf. (%)
€1.88
20.09.22
€1.60
20.09.23
-7.46%
03.10.22

Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Bed Bath & Beyond Inc.

Start price
Target price
Perf. (%)
€7.75
20.09.22
€3.00
20.09.23
-52.24%
11.01.23

Revenue growth >5% per year expected
Higher EBIT margin than peer group
Very low/no dividend yield expected
very negative Cash Flow expected
buy
Clovis Oncology Inc.

Start price
Target price
Perf. (%)
€1.17
20.09.22
-
20.09.23
-15.38%
15.10.22

Risky Investment
buy
Intercept Pharmaceuticals

Start price
Target price
Perf. (%)
€16.65
20.09.22
€32.00
31.01.23
-17.72%
30.09.22

Could be very worthwhile Investment >20% year
buy
Tricida

Start price
Target price
Perf. (%)
€10.34
20.09.22
€25.00
30.11.23
-93.82%
24.10.22

Could be very worthwhile Investment >20% year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€8.64
19.09.22
€17.00
19.09.23
-34.41%
17.10.22

Could be very worthwhile Investment >20% year
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€1.21
19.09.22
-
19.09.23
-12.19%
01.10.22

Capable Management
Could be very worthwhile Investment >20% year
Few uniques
buy
Vitesco Technologies Group AG

Start price
Target price
Perf. (%)
€49.82
19.09.22
€60.00
19.09.23
21.94%
30.05.23

Vivani Medical Inc.

Start price
Target price
Perf. (%)
€2.81
19.09.22
-
19.09.23
-67.84%
24.04.23

Probably not worthwhile Investment
Marathon Digital Holdings

Start price
Target price
Perf. (%)
€10.50
19.09.22
-
19.09.23
-8.86%
08.11.22

Could be worthwhile Investment >10% per year
Very high cyclical dependencies
buy
Athersys Inc.

Start price
Target price
Perf. (%)
€1.87
19.09.22
€3.80
19.09.23
0.19%
17.10.22

Could be very worthwhile Investment >20% year
buy
Hipay Group S.A.

Start price
Target price
Perf. (%)
€6.04
19.09.22
-
19.09.23
39.07%
10.08.23

Probably not worthwhile Investment
buy
Intercept Pharmaceuticals

Start price
Target price
Perf. (%)
€17.43
18.09.22
-
18.09.23
-17.30%
01.10.22

Risky Investment
Hipay Group S.A.

Start price
Target price
Perf. (%)
€6.04
17.09.22
€4.00
17.09.23
-30.88%
01.10.22

Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Business model of the past or high risk
Applied Optoelectronics Inc.

Start price
Target price
Perf. (%)
€3.73
17.09.22
€1.00
17.09.23
-26.73%
01.10.22

Revenue decline/stagnation expected
EBIT decline/stagnation expected
Bad rating
Below average Management
buy
ATOSS Software AG

Start price
Target price
Perf. (%)
€127.40
16.09.22
-
16.09.23
67.97%
16.09.23